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ABSTRACT 
Background: Fluoroquinolone antibiotics are often used for treatment of urinary tract infections. Prulifloxacin is a newer 
fluoroquinolone antimicrobial, and a prodrug of Ulifloxacin. It has been approved for use in Urinary tract infections and 
respiratory tract infections in many countries, but comparative studies comparing its efficacy against that of Levofloxacin are 
rare. Objectives: Our study aimed at studying this comparative efficacy. Methods: E. coli and Klebsiella spp. were isolated 
and identified from urine samples and their antibiogram was seen in respect to Levofloxacin and Prulifloxacin by Diak 
diffusion method. Antibiogram results were correlated with lecithinase, lipase and protease activities of the bac teria. Results: 
Most of the E. coli isolates were resistant to Prulifloxacin, but is was mostly effective against Klebsiella spp. Conclusion: 
Prulifloxacin is not a good option for empirical treatment of urinary tract infection, especially those caused by E. coli.  
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luoroquinolones are very useful for treating Urinary 
tract infections (UTI), and the commonly used ones 
are Levofloxacin and Ciprofloxacin [1]. Of these, 
Prulifloxacin is a new oral fluoroquinolone derivative with 
broad spectrum in-vitro activity, comparable with 
Ciprofloxacin, against various Gram negative 
uropathogenic bacteria [2]. Prulifloxacin, the prodrug of 
Ulifloxacin, can be administered once daily owing to its 
long elimination half life [3]. It has been found quite safe 
and efficacious in UTI and Respiratory tract infections in 
many Randomised Controlled Studies, especially from 
Europe, and the most common adverse effects observed 
after Prulifloxacin administration are nausea, vomiting, 
rashes and epigastric pain [4]. However, studies from our 
country comparing Prulifloxacin and Levofloxacin as 
regards in vitro efficacy against common uropathogens are 
very scant, although Prulifloxacin is now being routinely 
administered for pre-emptive treatment of UTI. Hence our 
study was planned to address these issues. 
MATERIALS AND METHODS 
This was a laboratory based observational study, carried 
out in Department of Microbiology of the institute, from 
June 2015 to September 2015. Ethics committee approval 
was not sought since this study involved only collection 
and presentation of routine data from laboratory and 
patients' identity was not going to be revealed. 
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Midstream urine samples collected routinely from the 
patients were inoculated on Cystine Lactose Electrolyte 
Deficient (CLED) agar (Himedia labs, Delhi, India) and 
incubated overnight. Colonies were observed for nature of 
colonies, and identified using Gram staining and standard 
biochemical tests. For example, E. coli was indole positive 
(in most cases), motile, citrate utilising and Urease 
negative. Klebsiella oxytoca was differentiated from K. 
pneumoniae by indole test (positive in K. oxytoca). 
Following identification, antibiotic susceptibility of the 
isolates was carried out using Kirby Bauer disk diffusion 
test as per CLSI protocol, using Levofloxacin (5 mcg) and 
Prulifloxacin (5 mcg) disk [5]. Susceptibility was 
interpreted using standard chart by measuring diameter of 
zone of inhibition. An isolate was taken to be Prulifloxacin 
resistant when this diameter was <15 mm, moderately 
sensitive when diameter was between 15 and 19 mm and 
sensitive when it was greater than 19 mm, following 
reports regarding interpretive criteria [6].  For levofloxacin 
the interpretive criteria and diameters were the same as per 
standard zone-size interpretive chart.  
After that, the isolates were streaked on Egg yolk agar 
prepared in-house (Nutrient agar, 90 ml + sterile beaten 
egg yolk, 10 ml), and incubated overnight at 37
0
C. 
Lecithinase activity was defined as distinct zone of 
opalescence around colonies on egg yolk agar, whereas 
lipase was defined as appearance of pearly sheen on 
surface of colonies. 
RESULTS 
Fifty four (54) urinary E. coli isolates were retrieved and 
tested, and it was seen that most of the E. coli isolates were 
resistant in vitro to Prulifloxacin (85.18%). Resistance to 
Levofloxacin was also quite high, in the order of 62.9%. 
On the other hand, only 4 isolates of K. oxytoca and 8 
of K. pneumoniae could be isolated in this period. Thus E. 
coli was about 6 times more commonly occurring in urine 
samples compared to Klebsiella spp. Most of the 
Klebsiella spp. (both species taken together) isolates were 
susceptbile to Prulifloxacin (41.6% resistance) and 
Levofloxacin (25% resistance). Lipase was found in all E. 
coli and Klebsiella spp. isolates. However, lecithinase and 
protease, both were found in 1 E. coli isolate, which was 
susceptible to Prulifloxacin. These 2 activities were not 
found in any Prulifloxacin resistant isolate. 
DISCUSSION 
Prulifloxacin is being widely used nowadays to 
empirically treat UTI and pneumonia [1,2]. It is generally 
more  active in vitro than other fluoroquinolone antibiotics 
against a variety of Gram negative bacteria, including E. 
coli, Pseudomonas aeruginosa, Morganella spp. and 
others, according to many recent studies [3]. This 
antibiotic is lipophilic in nature, approved for use in UTI 
and Lower Respiratory Tract Infection (LRTI) in Europe 
but still not in the USA, and is also being tried in the 
treatment of travellers' diarrhoea and also bacterial 
prostatitis [7]. After absorption, Prulifloxacin is 
metabolized by esterase enzymes to ulifloxacin; 
Prulifloxacin is absorbed mainly from the upper gut (upper 
small intestine) and then metabolized to ulifloxacin in the 
liver by α-esterase (paraoxonase) (first pass or presystemic 
metabolism) [8].  
Reports in literature are very few and far between, 
regarding resistance to this new drug in different Gram 
negative bacteria from urinary isolates in India. In a study 
from Chandigarh, North India, Mehta et al have found that 
there was no superior activity of Prulifloxacin over other 
fluoroquinolone antibiotics in treating UTI [9]. As far as 
we know, this is the first comparative study of 
Prulifloxacin with Levofloxacin as regards resistance in 
uropathogenic bacteria and correlation of the same with 
lecithinase and lipase acitivities from India, and further 
such studies are earnestly needed in this context. 
Prulifloxacin could really be a bad option, according to our 
findings, for empirically treating UTI caused by E. coli, 
but reasonably good when Klebsiella spp. is retrieved, 
pending susceptibility report, particularly in our area.  
CONCLUSION 
Prulifloxacin is not a good option for empirical treatment 
of urinary tract infection, especially those caused by E. 
coli. 
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